Having belatedly realised Donald Trump was serious about his tariff plans, economists have been ripping up their forecasts over the past week. The European Central Bank’s (ECB) monetary policy meeting ...

Traders have turned on the source of the problem, and the bond market that US President Donald Trump both derided and conceded to on Wednesday is back out to get him. The president’s 90-day tariff ...

It’s well known that Warren Buffett’s Berkshire Hathaway (US:BRK.B) had been offloading shares through 2024, significantly reducing US exposure, and ending the year with $325bn in cash, Treasury bills ...

The team unpack yet another fallout from a Donald Trump announcement, how to invest in unlisted assets, and a recruiter’s results ...

London-based social and digital media group Brave Bison (BBSN:2.6p) has announced the acquisition of News UK’s influencer ...

The optimism carried over into Asia’s Thursday session with the Nikkei 225 shooting up 9 per cent, while the Hang Seng and ...

Any small company is risky, and ultimately it needs its customers and potential customers to have enough money to invest in the marketing software. But on almost every metric, Eagle Eye is as cheap as ...

When a company embarks on a megadeal, it can end up with dangerously high debt levels. Alternatively, shareholders can see their holdings massively diluted. In this case, though, the Exxon sticker ...

Trading superpower China – long a target for Trump – has responded in kind to the now-triple load of tariffs slapped on its US exports. A concern for other nations is that China’s unwanted exports ...

Ruffer (RICA) has made a share price total return of around 3 per cent, with Capital Gearing (CGT) and Personal Assets (PNL) investors down by around 1.5 per cent. BH Macro (BHMG), the enigmatic hedge ...

hVIVO ( HVO:15p ), a specialist contract research organisation (CRO) testing infectious and respiratory disease vaccines and antivirals using human challenge trials (HCT), flagged up its record annual ...

Aviva’s (AV) controversial plan to buy preference shares back from investors has received strong support – but it is still unknown whether the insurer will be able to cancel the instruments entirely.